journal article·2014-08Open access

Post-transcriptional regulation in osteoblasts using localized delivery of miR-29a inhibitor from nanofibers to enhance extracellular matrix deposition

Eric N. James, Anne M. Delany, Lakshmi S. Nair

Acta Biomaterialia· Volume 10· Issue 8

Abstract

MicroRNAs are important post-transcriptional regulators of skeletal biology, and miRNA-based therapeutics have the potential to aid bone repair. However, efficient tools for delivering miRNA mimics or inhibitors to specific target tissues are limited. Polymeric nanofibers closely mimic natural extracellular matrix (ECM) morphology, and are attractive candidates for supporting delivery of cells and bone-anabolic reagents. It is hypothesized that gelatin nanofibers could be used for the localized transient delivery of miRNA-based therapeutics, using miR-29a inhibitor as a prototype to increase ECM deposition. miR-29 family members are negative regulators of ECM synthesis, targeting the mRNAs of selected collagens and osteonectin/SPARC. Inhibiting miR-29 activity may therefore increase ECM production by cells. miR-29a inhibitor-loaded gelatin nanofibers, prepared by electrospinning, demonstrated continuous release of miRNA inhibitor over 72h. Pre-osteoblastic murine MC3T3-E1 cell line seeded on miR-29a inhibitor-loaded nanofibers synthesized more osteonectin, indicating efficient inhibitor delivery. These cells also displayed increased Igf1 and Tgfb1 mRNA. Moreover, primary bone marrow stromal cells from transgenic pOBCol3.6cyan reporter mice, grown on miR-29a inhibitor scaffolds, displayed increased col3.6 cyan expression as well as collagen production. This study demonstrates that ECM mimicking nanostructured scaffolds, in conjunction with bioactive miRNA-based therapeutics, may serve as a novel platform for developing biologically active localized cell delivery systems.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Bone Tissue Engineering Materials · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (45)

Show source-provided references
1. MicroRNA biogenesis and regulation of bone remodeling10.1186/ar3325 ↗
2. MicroRNA 199b–5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines10.1007/s00210-013-0837-4 ↗
3. Nair · 2008
4. [MicroRNAs and nonresolving inflammation-related cancer]. Zhong nan da xue xue bao Yi xue ban
5. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases10.1016/j.biochi.2013.03.010 ↗
6. MicroRNA in HCV infection and liver cancer10.1016/j.bbagrm.2011.07.010 ↗
7. MicroRNAs as early biomarkers in obesity and related metabolic and cardiovascular diseases10.2174/13816128113199990364 ↗
8. MiR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling10.1002/jcb.22243 ↗
9. MiR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop10.1074/jbc.M110.116137 ↗
10. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis10.1681/ASN.2011010055 ↗
11. Cartilage and bone extracellular matrix10.2174/138161209787846739 ↗
12. Matricellular proteins: extracellular modulators of bone development, remodeling, and regeneration10.1016/j.bone.2005.11.017 ↗
13. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation10.1074/jbc.M809787200 ↗
14. Self-assembling modified beta-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington’s disease10.1021/mp3003946 ↗
15. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy10.1038/nm.2617 ↗
16. Bioengineered nanoparticles for siRNA delivery10.1002/wnan.1233 ↗
17. The role of electrospinning in the emerging field of nanomedicine10.2174/138161206779026326 ↗
18. Polymers as biomaterials for tissue engineering and controlled drug delivery
19. Fabrication and evaluation of resveratrol loaded polymeric nanofibers10.1166/jbt.2012.1049 ↗
20. Development and characterization of lactoferrin loaded poly(ε-caprolactone) nanofibers10.1166/jbn.2014.1717 ↗
21. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage10.1359/jbmr.2002.17.1.15 ↗
22. Distribution of noncollagenous proteins in the matrix of adult human bone: evidence of anatomic and functional heterogeneity10.1002/jbmr.5650080902 ↗
23. Visualizing levels of osteoblast differentiation by a two-color promoter-GFP strategy: type I collagen-GFPcyan and osteocalcin-GFPtpz10.1002/gene.20156 ↗
24. Influences of physical and chemical crosslinking techniques on electrospun type A and B gelatin fiber mats10.1016/j.ijbiomac.2010.06.008 ↗
25. Crosslinking of the electrospun gelatin nanofibers10.1016/j.polymer.2006.02.046 ↗
26. Cell adhesion and proliferation enhancement by gelatin naofiber scaffolds10.1177/0883911511423563 ↗
27. The effect of controlled release of PDGF-BB from heparin-conjugated electrospun PCL/gelatin scaffolds on cellular bioactivity and infiltration10.1016/j.biomaterials.2012.06.017 ↗
28. PCL and PCL-gelatin nanofibers as esophageal tissue scaffolds: optimization, characterization and cell-matrix interactions10.1166/jbn.2013.1653 ↗
29. TGF-beta3 immobilized PLGA-gelatin/chondroitin sulfate/hyaluronic acid hybrid scaffold for cartilage regeneration10.1002/jbm.a.32899 ↗
30. Preparation and characterization of electrospun PLGA/gelatin nanofibers as a drug delivery system by emulsion electrospinning10.1080/09205063.2012.728193 ↗
31. Release kinetics and in vitro bioactivity of basic fibroblast growth factor: effect of the thickness of fibrous matrices10.1002/mabi.201000222 ↗
32. RNA interference by nanofiber-based siRNA delivery system10.1016/j.jconrel.2010.02.003 ↗
33. Electrospinning of gelatin fibers and gelatin/PCL composite fibrous scaffolds10.1002/jbm.b.30128 ↗
34. Fiber diameters control osteoblastic cell migration and differentiation in electrospun gelatin10.1002/jbm.a.32756 ↗
35. Osteoblasts responses to three-dimensional nanofibrous gelatin scaffolds10.1002/jbm.a.34253 ↗
36. Commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage10.1073/pnas.0403100101 ↗
37. Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I10.1038/mt.2013.55 ↗
38. IGF-1 and bone: new discoveries from mouse models10.1002/jbmr.234 ↗
39. IGF-I 3’ untranslated region: strain-specific polymorphisms and motifs regulating IGF-I in osteoblasts10.1210/en.2012-1476 ↗
40. Tang SY, Alliston T. Regulation of postnatal bone homeostasis by TGF[beta]. BoneKEy Reports, http://dx.doi.org/10.1038/bonekey.2012.255.10.1038/bonekey.2012.255 ↗
41. TGF-beta accelerated the osteogenic differentiation of bone marrow cells induced by collagen matrix10.1006/bbrc.1995.1923 ↗
42. TGF-beta regulation of osteoblast differentiation and bone matrix properties
43. TGF-beta/Smad3 signaling promotes renal fibrosis by inhibiting miR-2910.1681/ASN.2010121308 ↗
44. Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts10.1371/journal.pone.0033766 ↗
45. Differential utilization of regulatory domains within the alpha 1(I) collagen promoter in osseous and fibroblastic cells10.1083/jcb.116.1.227 ↗